Figure 1.

Short-term (72 h) sulforhodamine B (SRB) assay results on melanoma cell lines after treatment with different concentrations of zoledronic acid (ZA) or bisphosphonate (BPH). (A) BRAF mutant A375 and WM35, (B) BRAF and PTEN mutant A2058 and WM239 (C) NRAS mutant M24met and WM3060, and (D) BRAF, PTEN, and NRAS wild-type MEWO and VM47 cell lines. All lines were more sensitive to BPH than ZA, except for the NRAS mutant M24met cell line, where ZA was more effective. Data are shown as the mean ± SEM from at least three independent measurements. Asterisks mean a significant difference between BPH and ZA by * p < 0.05, ** p < 0.01, and *** p < 0.001. (E) The graph shows the efficacy of BPH compared to ZA by the ZA/BPH ratio of the averages. Results are from the short-term (72 h) viability assays, as one point is the average of all of the given mutation group viability data at the indicated concentration. Data are shown as the mean ± SEM from at least eight independent experiments. (F) IC₅₀ values upon treatment with ZA or BPH for 72 h.